

## **M. Kathleen Behrens Wilsey, Ph.D.**

Dr. Behrens Wilsey served as a Member of the President's Council of Advisors on Science and Technology (PCAST), from 2001 to 2009, working on multiple national policy matters. She Chaired PCAST's Subcommittee on Personalized Medicine and led a two year study that culminated in the September 15, 2008 report, *Priorities for Personalized Medicine*. Kathy was a director of the Board on Science, Technology and Economic Policy (STEP) for the National Research Council from 1997-2005, at which time she participated as a member of the Institute of Medicine Committee on New Approaches to Early Detection and Diagnosis of Breast Cancer. Kathy was a director of the National Venture Capital Association from 1993 to 2000, also serving as President, Chairman and Past Chairman from October of 1999 through April of 2000.

Dr. Behrens Wilsey was a Co-Founder of the Coalition for 21<sup>st</sup> Century Medicine and currently serves as a Steering Committee member of that organization. She also is a member of the Board of Directors of Sarepta Therapeutics, Inc. and KEW Group Inc. Kathy holds a Ph.D. in Microbiology from the University of California, Davis.

Kathy established a career in the financial services industry, working with Robertson Stephens & Co. until 1996, where she became a general partner and managing director. Dr. Behrens Wilsey continued in her capacity as a General Partner for selected venture funds for RS Investments, after management led a buy-out of that firm from Bank of America. Her professional career includes tenures as a public-market life-sciences securities analyst, as well as venture capitalist focusing on healthcare and technology investments. She was instrumental in the founding of several life-sciences companies including Protein Design Labs, Inc. and COR Therapeutics, Inc. and participated in financing a broad range of health care services and products companies.

Dr. Behrens Wilsey served as a director of Abgenix, Inc. in a role that spanned that firm's early rounds of private financings through the company's sale in 2006 to Amgen, Inc. and was a director of Amylin Pharmaceuticals, Inc. from 2009 until the company's sale in 2012 to Bristol-Myers Squibb Co. Dr. Behrens Wilsey has worked for the last several years with KEW Group Inc. in developing a personalized medicine oncology management company and served as KEW Group's President & CEO from January 2012 through June 2014.

**Committee on Energy and Commerce**  
**U.S. House of Representatives**  
Witness Disclosure Requirement - "Truth in Testimony"  
Required by House Rule XI, Clause 2(g)

<b>1. Your Name: M. Kathleen Behrens Wilsey, Ph.D.</b>		
2. Are you testifying on behalf of a Federal, State, or Local Government entity?	Yes	No <b>X</b>
3. Are you testifying on behalf of an entity other than a Government entity?	Yes	No <b>X</b>
4. Other than yourself, please list what entity or entities you are representing:  <p style="text-align: center;"><b>The Coalition for 21st Century Medicine</b></p>		
5. Please list any Federal grants or contracts (including subgrants or subcontracts) that <u>you or the entity you represent have received</u> on or after October 1, 2011:		
6. If your answer to question number 3 is yes, please describe your position or representational capacity with the entity or entities you are representing:  <p style="text-align: center;"><b>Co-Founder and Member, Steering Committee</b></p>		
7. If your answer to question number 3 is "yes," do any of the entities disclosed in question number 4 have parent organizations, subsidiaries, or partnerships to the entities for whom you are not representing?	Yes	No <b>X</b>
8. If the answer to question number 3 is "yes," please list any Federal grants or contracts (including subgrants or subcontracts) which were received by the entities listed under question 4 on or after October 1, 2011, that exceed 10 percent of the revenue of the entities in the year received, including the source and amount of each grant or contract to be listed:		

**None**

9. Please attach your curriculum vitae to your completed disclosure form.

Signature:



Date: *September 5, 2014*